WESTPORT, Conn., Sept. 5,
2023 /PRNewswire/ -- Intensity Therapeutics,
Inc. (Nasdaq: INTS), a clinical-stage biotechnology company
focused on the discovery and development of proprietary, novel
immune-based intratumoral cancer therapies designed to kill tumors
and increase immune system recognition of cancers, today announced
that Lewis H. Bender, President and
Chief Executive Officer, will present a company overview at the
H.C. Wainwright 25th Annual Global Investment Conference
on Monday, September 11, at
4:30 pm ET.
Mr. Bender will also host in-person and virtual one-on-one
meetings during the event. Institutional investors who are
registered for the conference can log into www.hcwevents.com to
request a meeting with the company.
A live webcast of the presentation can be accessed here and
will be available on the Intensity Therapeutics website at:
https://ir.intensitytherapeutics.com/news-events/events-presentations.
An archived replay will be available on the company's website for
approximately 90 days following the conclusion of the
conference.
About Intensity Therapeutics
Intensity
Therapeutics, Inc. is a clinical-stage biotechnology company
pioneering a new immune-based approach to treat solid tumor
cancers. Intensity leverages its DfuseRx℠ technology platform to
create proprietary drug formulations that following direct
injection rapidly disperse throughout a tumor and diffuse
therapeutic agents into cancer cells. Intensity's product
candidates have the potential to induce an adaptive immune response
that not only attacks the injected tumor, but also non-injected
tumors. The Company's lead product candidate, INT230-6, is in
development for the treatment of patients with solid tumors, such
as sarcoma and breast cancer. Intensity has a clinical
collaboration agreement with Merck Sharpe & Dohme (Merck) to
evaluate INT230-6 with pembrolizumab. In addition, the Company has
a clinical collaboration agreement with Bristol-Myers Squibb to
evaluate the combination INT230-6 with Bristol-Myers Squibb's
anti-CTLA-4 antibody, ipilimumab. Intensity has also executed
agreements with the Ottawa Hospital Research Institute (OHRI) and
the Ontario Institute of Cancer Research (OICR) to study INT230-6
in a randomized controlled neoadjuvant phase 2 study in women with
early stage breast cancer (the INVINCIBLE study) (NCT04781725).
Additionally, the Company executed a Cooperative Research and
Development Agreement (CRADA) with the National Cancer Institute's
(NCI) Vaccine Branch. For more information, please visit
www.intensitytherapeutics.com and follow the Company on Twitter
@IntensityInc.
Forward-Looking Statements
Certain statements in
this press release may constitute "forward-looking statements"
within the meaning of the United States Private Securities
Litigation Reform Act of 1995, as amended to date. These statements
include, but are not limited to, statements relating to the
expected future plans, development activities, projected
milestones, business activities or results. We have based these
forward-looking statements on our current expectations and
projections about future events, nevertheless, actual results or
events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, include: the risk that the anticipated
milestones may be delayed or not occur or be changed, as well as
other risks described in the section entitled "Risk Factors" in the
Company's SEC filings, which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations and beliefs. The Company does not plan to
update any such forward-looking statements and expressly disclaims
any duty to update the information contained in this press release
except as required by law.
Investor Relations Contact:
Argot
Partners
Jonathan Nugent
Intensity@argotpartners.com
Media Contact:
Argot Partners
David Rosen
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301916149.html
SOURCE Intensity Therapeutics, Inc.